World Health Organization Sounds Concern Over Critical Lack of Obesity Injections

Less than a tenth of people who could benefit from weight-loss injections like Wegovy can access them, states the global health agency as it issues its initial recommendations on the drugs.

Given more than one billion people worldwide now living with obesity, it is calling for increased and just access to GLP-1 medication.

Per forecasts, in excess of 2,000,000,000 are projected to be obese by 2030 unless action is taken.

"Our latest guidelines acknowledges that obesity is a lifelong illness that can be addressed with thorough and lifelong care," remarked the agency's head Tedros Adhanom Ghebreyesus.

Significant expense, limited production capacity, and logistical bottlenecks are key barriers to universal access to the jabs that can help people shift substantial weight, says the body.

Weight-Loss Drug Scarcity

Even in the current most optimistic case, the supply of GLP-1 therapies could only cover around 100 million people – under 10% of those who need them, as stated by the WHO.

The advice calls on governments and firms to expand availability, by approaches including licensing agreements.

The intellectual property rights on the active ingredient – the main component of a leading brand – is set to lapse in several nations in 2026.

The Way Obesity Injections Work

GLP-1 drugs imitate a natural hormone to reduce digestion speed, suppress the appetite and increase satiety so people reduce food intake.

Individuals usually start to lose weight in the initial weeks of commencing the once-weekly jabs.

Research points to people may see weight return after a year of discontinuing the drug, because their normal appetite resume.

Being carrying excess weight increases your risk for developing diseases, such as type 2 diabetes, cardiovascular issues, stroke, and specific malignancies.

Excess weight concerns individuals in every country and was responsible for 3.7 million fatalities worldwide in 2024, as per the WHO.